Phyton Biotech
- Company typePrivate
- Founded1990
- HeadquartersDelta, Canada
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
Phyton Biotech firmographics
Firmographics- Name
- Phyton Biotech
- Legal name
- Phyton Biotech GmbH
- Website
- https://phytonbiotech.com
- Company type
- Private
- Founded year
- 1990
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Ownership category
- akta.pro rank
Phyton Biotech industry classification
Industry- Product category
- Contract Pharmaceutical API Manufacturing (Plant Cell Fermentation CDMO)
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254), Medicinal and Botanical Manufacturing (325411)
- SIC
- Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Small-Molecule API & Intermediates CDMO (HLAGABAA)
- akta.pro secondary industries
- Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK)
Keywords
Where Phyton Biotech is headquartered
LocationHeadquarters
- HQ city
- Delta
- HQ country
- Canada
- HQ region
- North America
Offices3 records
Markets served
Phyton Biotech business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Personnel, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales
Revenue model
- Active Pharmaceutical Ingredients (API) Sales: Production and sale of API-grade paclitaxel and docetaxel as the world's largest supplier of these products via PCF technology. Revenue generated from product sales to pharmaceutical manufacturers.
- Contract Manufacturing Services: Full range of integrated contract product and process development and commercial manufacturing services across the entire development chain, from feasibility to commercial production. Includes specialty fermentation and commercial downstream processing.
- Reference Standards: Sale of reference standard products including paclitaxel, docetaxel, and related compounds for laboratory use. Products sold in 10mg packaging with prepaid payment terms.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | API products (Paclitaxel, Docetaxel) - custom quotation based |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels6 records
Phyton Biotech product offering
Product offeringCore offering
Phyton Biotech is a contract development and manufacturing organization (CDMO) that produces pharmaceutical active ingredients (APIs) using proprietary plant cell fermentation (PCF®) technology. Its portfolio includes the anti-cancer APIs Paclitaxel and Docetaxel, the QS-21 vaccine adjuvant, reference standards, and custom fermentation/downstream processing services for clients developing complex plant-derived compounds such as the antibiotic Corallopyronin A. The company serves pharmaceutical, biotech, and research organizations requiring sustainable, scalable, and GMP-compliant supply of high-value botanical APIs.
Product overview
Phyton Biotech is a specialty fermentation company operating the world's largest plant cell fermentation (PCF®) facility, serving as a CDMO (Contract Development and Manufacturing Organization) for the pharmaceutical and related industries. The core offering is the proprietary PCF® technology platform for sustainable production of high-value phytochemicals. The product portfolio centers on two flagship APIs—Paclitaxel and Docetaxel—produced via plant cell fermentation, making Phyton the world's largest supplier of these cancer drugs. Additional offerings include specialty fermentation contract services (from feasibility through commercial production), commercial downstream processing, and an extensive catalog of over 30 reference standards for taxane compounds. Recent developments include Corallopyronin A (anti-infective) technology transfer and QS-21 vaccine adjuvant production via plant cell culture. The company operates GMP-certified facilities in Germany and Canada with over 200 m³ of installed fermentation capacity.
Differentiator
Problem solved
Functional benefit
Products and services
- Paclitaxel API
Quantifiable outcome
- 80-92% reduction in solvent usage compared to traditional paclitaxel manufacturing processes
- +3 more outcomes
Companies that use Phyton Biotech
Customer profileNamed customers4 records
Segments5 records
Ideal customer profiles2 records
Phyton Biotech technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
Phyton Biotech partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and minor.
- University Hospital Bonn (UKB)coreCollaboration in Corallopyronin A development for neglected tropical diseases. UKB leads the broader clinical development program for this novel anti-infective agent targeting filarial infections such as river blindness and lymphatic filariasis.
- Helmholtz Centre for Infection Research (HZI)corePartner in Corallopyronin A development consortium; developed the optimized heterologous production strain of Myxococcus xanthus for CorA manufacturing under Prof. Rolf Müller's leadership.
- German Center for Infection Research (DZIF)coreSupports the broader clinical development program for Corallopyronin A as a new treatment for diseases disproportionately affecting underserved populations. Key coordinator of international collaboration.
- Eisai Co. Ltd.minorCollaboration through GHIT Fund for advancing Corallopyronin A as a treatment option for neglected tropical diseases in collaboration with academic institutions.
- PellePharmminorSuccessfully established high-yielding plant cell lines of cyclopamine source for PellePharm's patedigib topical gel targeting rare dermatologic conditions using PCF technology.
Scale indicators10 records
Recent moves6 records
Expansion highlights6 records
Phyton Biotech competitors and assessment
Company assessmentBroad incumbents
- DSM-Firmenich (Animal Nutrition & Health / i-Health): Specialty ingredients and fermentation-derived nutraceutical/pharmaceutical ingredient producer with large-scale fermentation assets. Comparable to Phyton in the use of industrial fermentation for high-value ingredients, though DSM operates across a much broader specialty ingredients portfolio.
- Thermo Fisher Scientific (Patheon CDMO): Global CDMO services including API manufacturing, biologics, and sterile fill-finish across hundreds of programs. Comparable to Phyton as a diversified contract manufacturer serving pharma, with substantially larger scale and scope.
- Lonza Group: Global CDMO leader with large-scale microbial and mammalian fermentation capacity for APIs and biologics. Comparable to Phyton as a contract manufacturer of complex pharmaceutical inputs at industrial scale, though Lonza operates across a much broader portfolio than Phyton's plant-cell-fermentation niche.
- Catalent: Global CDMO providing development and manufacturing for small molecules and biologics, including fermentation-based services. Comparable to Phyton as a contract API/biological manufacturer serving pharma, with substantially broader service breadth.
- WuXi Biologics: Major biologics CDMO with extensive microbial and mammalian fermentation capacity. Comparable to Phyton as a global GMP contract manufacturer for complex therapeutics, though WuXi operates at significantly larger scale and primarily in mammalian systems.
- Samsung Biologics: Large-scale biologics CDMO with multi-site GMP manufacturing for monoclonal antibodies and recombinant proteins. Comparable to Phyton as a high-capacity GMP contract manufacturer serving global pharma, though Samsung focuses on mammalian biologics rather than plant-cell fermentation.
Direct peers
- Evotec: Contract development and manufacturing organization offering process development, clinical and commercial manufacturing for small molecules and biologics. Comparable to Phyton as a fermentation-capable CDMO serving pharma, with a more discovery-led service model.
- BioVectra: CDMO specializing in microbial fermentation, complex small molecules, and biologics manufacturing for pharmaceutical clients. Closely comparable to Phyton as a fermentation-focused CDMO with cGMP capacity and a focus on high-value APIs.
- AGC Biologics: CDMO offering microbial and mammalian cell-based biopharmaceutical manufacturing including recombinant proteins and APIs. Comparable to Phyton as a mid-sized, multi-site GMP contract manufacturer with fermentation expertise and a focus on complex molecules.
Emerging players
- Ayana Bio: US-based plant cell fermentation company developing bioactive ingredients for cosmetics, food, and supplements using proprietary plant cell culture technology. Directly comparable to Phyton in using plant cell fermentation for high-value ingredients, though at an earlier commercial stage and in different end-markets.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Phyton Biotech social profiles
Digital presencePhyton Biotech compliance and trust
Trust signalCompliance12 records
Phyton Biotech financial estimates
Financial estimateRevenue estimate
Valuation estimate
Phyton Biotech leadership team
Management profileNumber of profiles
Profiles4 records
Phyton Biotech funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Phyton Biotech M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Phyton Biotech
What does Phyton Biotech do?
Phyton Biotech is a contract development and manufacturing organization (CDMO) that produces pharmaceutical active ingredients (APIs) using proprietary plant cell fermentation (PCF®) technology. Its portfolio includes the anti-cancer APIs Paclitaxel and Docetaxel, the QS-21 vaccine adjuvant, reference standards, and custom fermentation/downstream processing services for clients developing complex plant-derived compounds such as the antibiotic Corallopyronin A. The company serves pharmaceutical, biotech, and research organizations requiring sustainable, scalable, and GMP-compliant supply of high-value botanical APIs.
Is Phyton Biotech a public or private company?
Phyton Biotech is a private company. It is classified as unknown and is currently operating.
When was Phyton Biotech founded?
Phyton Biotech was founded in 1990. It employs 51 to 100 people.
Where is Phyton Biotech based?
Phyton Biotech is headquartered in Delta, Canada, in the North America region.
How does Phyton Biotech make money?
Three revenue lines are on record. Active Pharmaceutical Ingredients (API) Sales are the primary driver. The others are contract Manufacturing Services and reference Standards.
Who are Phyton Biotech's main competitors?
Broad incumbents on record are DSM-Firmenich (Animal Nutrition & Health / i-Health), Thermo Fisher Scientific (Patheon CDMO), Lonza Group, Catalent, WuXi Biologics and Samsung Biologics. Direct peers are Evotec, BioVectra and AGC Biologics. Ayana Bio is listed as an emerging player.
Does Phyton Biotech have an API?
No public API is recorded for Phyton Biotech.
What industry is Phyton Biotech in?
Phyton Biotech's product category is Contract Pharmaceutical API Manufacturing (Plant Cell Fermentation CDMO). Its primary akta.pro industry code is HLAGABAA, Small-Molecule API & Intermediates CDMO, with a secondary code of HLAGABAC, Biologics (mAbs/Recombinant Proteins) CDMO. Its NAICS code is 3254 and its SIC code is 2834.